Bruker (NASDAQ:BRKR) Releases Earnings Results, Beats Expectations By $0.08 EPS

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Wednesday. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08, FiscalAI reports. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $796.11 million. During the same period last year, the business earned $0.47 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Q1 results beat expectations with reported revenue of $823.4M (+2.7% reported, organic -4.4%) and non‑GAAP EPS of $0.31, and management reconfirmed full‑year guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS.
• Order momentum strengthened—BSI organic bookings grew in the high single digits and book‑to‑bill stayed >1 for the third consecutive quarter—management expects a return to organic revenue growth in Q2 (low‑ to mid‑single digits).
• Several idiosyncratic, AI‑driven growth engines are accelerating performance, including semi‑metrology (now >$300M annual), SciY lab‑digitization/software (~$50M), security detection (~$70M), and large multi‑year BEST superconductor orders, which management says provide durable secular tailwinds.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%) by FX, tariffs and mix, but management expects a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by cost‑savings (now tracking ~$140M annualized), though execution and macro risks remain.

Bruker Trading Up 11.3%

NASDAQ BRKR traded up $4.29 during trading hours on Wednesday, reaching $42.30. The company had a trading volume of 3,145,917 shares, compared to its average volume of 1,924,247. The stock has a 50-day moving average of $37.18 and a 200 day moving average of $42.01. Bruker has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $6.44 billion, a P/E ratio of -282.00, a price-to-earnings-growth ratio of 2.28 and a beta of 1.12.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio is presently -133.33%.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Several hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Bruker by 6.7% in the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 380 shares during the period. Parallel Advisors LLC lifted its holdings in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Bruker in the fourth quarter valued at $26,000. Finally, UMB Bank n.a. raised its stake in shares of Bruker by 57.9% during the 4th quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock worth $74,000 after buying an additional 576 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Barclays lowered their target price on shares of Bruker from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. TD Cowen raised shares of Bruker to a “hold” rating in a report on Monday, April 13th. UBS Group reissued a “neutral” rating and issued a $49.00 price target on shares of Bruker in a report on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on shares of Bruker in a report on Thursday, February 12th. Finally, The Goldman Sachs Group lowered their target price on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker presently has an average rating of “Hold” and an average price target of $49.38.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 results beat expectations — Bruker reported EPS of $0.31 vs. consensus $0.23 and revenue of $823.4M vs. $796.1M estimates, showing a quarter that topped analyst forecasts. Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management provided FY2026 EPS guidance (2.10–2.15) roughly in line with consensus, reducing uncertainty about the year and giving investors a clear earnings range to model. Bruker Earnings / Press Release & Transcript
• Neutral Sentiment: Revenue growth was modest (up ~2.7% YoY), indicating steady top‑line expansion but not a strong acceleration — the beat was driven mainly by execution rather than a big demand surge. Bruker: Q1 Earnings Snapshot
• Negative Sentiment: EPS declined versus the prior year (from $0.47 to $0.31) and net margin remains slightly negative (-0.25%), highlighting margin pressure and profit recovery still in progress. Bruker Earnings / Press Release & Transcript
• Negative Sentiment: Market concerns about earnings jitters and insider selling have been raised in recent commentary, which could cap upside if investors turn cautious despite the beat. Does Earnings Jitters And Insider Selling Change The Bull Case For Bruker (BRKR)?

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.